Answers are grounded in this paper and cite their sources.
Background & AimsHepatitis E virus is a single-stranded RNA virus that is estimated to cause over 20 million infections worldwide. The lack of an HEV-specific antiviral, leaves drug repurposing as a fast-tracked option to help patients with symptomatic infection. Recently, sofosbuvir has been shown to have antiviral activity against HEV in vivo. However, a variant, A1343V, that is strongly associated with viral relapse impedes treatment success. In this study, we investigated the occurrence of variants during sofosbuvir and ribavirin treatment in vivo and assessed the sensitivity of resistance-associated variants to concurrent treatment in cell culture.MethodsTwo patients with chronic HEV infection that did not clear infection under ribavirin treatment were followingly treated with a combination of sofosbuvir and ribavirin. We determined response to treatment by measuring liver enzymes and viral load in blood and stool. Moreover, we analyzed virus evolution using polymerase-targeted high-throughput sequencing and assessed replication fitness of resistance-associated variants using a HEV replicon system.ResultsCombination treatment was successful in decreasing viral load towards the limit of quantification. However, during treatment sustained virological response was not achieved. Variants associated with sofosbuvir or ribavirin treatment emerged during treatment, including A1343V and G1634R. Moreover, A1343V, as single or double mutation with the G1634R showed sofosbuvir resistance during concomitant treatment in vitro.ConclusionsThese results highlight the importance of variant profiling during antiviral treatment of patients with chronic infection. Understanding how intra-host virus evolution impedes with treatment success will help designing the next generation antivirals.Impact and implicationsThe lack of HEV-specific antivirals to treat chronic infection remains a serious health burden. Although ribavirin, interferon and sofosbuvir have been reported as anti-HEV drugs, not all patients are eligible for treatment or clear infection, since resistant-associated variants can rapidly emerge. In this study, we analyzed the efficacy of sofosbuvir and ribavirin combination treatment in terms of HEV suppression, the emergence of resistance-associated variants and their ability to escape treatment inhibition in vitro. Our results provide novel insights into evolutionary dynamics of HEV during treatment and thus inform the next generation of antiviral treatments.
No takes yet. Share an insight, caveat, or question.
Gömer et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: